Back to 2015 Joint Annual Meeting

INTRODUCTION:
Men with BPH can present with urinary retention. The use of GreenLight 180W-XPS, a minimally invasive procedure has not been evaluated for its effectiveness in men presenting with urinary retention. We interrogated a large retrospective database to compare outcomes for men in urinary retention.
MATERIALS & METHODS:
Data on 928 patients with clinical BPH treated with GreenLight 180W-XPS were collected retrospectively from 5 centers. 204 men presented in urinary retention. Several clinical factors were ascertained to document efficacy and safety in men including: procedure time, energy applied in joules, postop catheterization time, IPSS, QOL, PVR and reoperation rates.
RESULTS:
The total procedure time and amount of energy used were greater in the retention group. However, postoperative IPSS, QOL, length of catheterization, reoperation rate, and proportion with adverse events were all similar between the two groups. PVR in the urinary retention group difference of 24 cc is not clinically meaningful
CONCLUSIONS:
PVP with GreenLight 180W-XPS is a safe, effective method of treating patients with BPH who present with catheter dependent urinary retention. There was a low reoperation rate and very few adverse events. The results show excellent outcomes with PVP in patients with advanced BPH who present with urinary retention.

TABLE 1	Group
Variable	Retention (N = 204)	No (N = 724)	Total (N = 928)	p-value
Procedure time, min	70.7 ± 32.4 (12.0, 64.0, 193.0) n = 195	52.8 ± 26.1 ( 15.0, 47.0, 210.0 ) n = 684	56.8 ± 28.5 ( 12.0, 50.0, 210.0 ) n = 879	< 0.001
Energy applied, kJ	344.5 ± 208.0 ( 20.0, 303.5, 1103.6 ) n = 204	250.8 ± 161.2 ( 14.5, 205.3, 1006.2 ) n = 722	271.5 ± 176.8 ( 14.5, 225.0, 1103.6 ) n = 926	< 0.001
Length of catheterization, days	1.4 ± 1.4 ( 0.3, 1.0, 14.0 ) n = 180	1.1 ± 0.9 ( 0.1, 1.0, 10.0 ) n = 502	1.2 ± 1.1 ( 0.1, 1.0, 14.0 ) n = 682	0.209
IPSS, post-op	5.6 ± 4.7 ( 0.0, 5.0, 28.0 ) n = 129	6.5 ± 5.8 ( 0.0, 5.0, 32.0 ) n = 423	6.3 ± 5.5 ( 0.0, 5.0, 32.0 ) n = 552	0.409
IPSS, post-op <=8 9 to 21 greater than 21	82.2% ( 106) 16.3% ( 21) 1.6% ( 2) n = 129	74.8% (320) 22.0% ( 94) 3.3% (14) n = 428	76.5% (426) 20.6% ( 115) 2.9% ( 16) n = 557	0.218
IPSS-QoL, post-op	1.1 ± 1.1 ( 0.0, 1.0, 6.0 ) n = 124	1.4 ± 1.3 ( 0.0, 1.0, 6.0 ) n = 403	1.3 ± 1.3 ( 0.0, 1.0, 6.0 ) n = 527	0.079
Post void residual, post-op	65.4 ± 120.1 ( 0.0, 26.5, 999.0 ) n = 118	41.8 ± 88.4 ( 0.0, 15.0, 954.0 ) n = 450	46.7 ± 96.2 ( 0.0, 15.5, 999.0 ) n = 568	< 0.001
*Results are presented as percentage (count) or mean ± standard deviation (min, median, max). p-value is from statistical test of difference between groups.

TABLE 2		Group*
Event	Time Point (days)	Retention†	No†	Total†	Group Difference**
Urinary tract infection	90	4.5% (9) [ 2.4% to 8.4% ]	2.4% (17) [ 1.5% to 3.8% ]	2.8% (26) [1.9% to 4.2% ]	2.1% [ -1.0% to 5.2% ]
Stricture or BNC	365	1.0% (2) [ 0.3% to 4.1% ]	2.0% (13) [ 1.2% to 3.5% ]	1.8% (15) [ 1.1% to 3.0% ]	-1.0% [ -2.8% to 0.8% ]
Retention	90	6.4% (13) [ 3.8% to 10.8% ]	3.4% (24) [ 2.3% to 5.0% ]	4.0% (37) [ 2.9% to 5.5% ]	3.0% [ -0.6% to 6.7% ]
Surgical retreatment	365	2.8% (5) [ 1.2% to 6.5% ]	2.1% (14) [ 1.3% to 3.6% ]	2.3% (19) [ 1.5% to 3.6% ]	0.6% [ -2.0% to 3.2% ]
* Results presented are Kaplan-Meier estimate for proportion of subjects with event (number of subjects) [95% confidence interval] † Complementary log-log confidence interval presented ** Linear confidence interval presented